Next Day Disclosure Return
Filed with HKEX · Stock code 460 · · 5 pages · English
Sihuan Pharmaceutical Holdings Group Ltd. on 6ix
Earlier from Sihuan Pharmaceutical
- Voluntary announcement - new indication of xuanzhu biopharm's Bireociclib included in the 2026 NRDL
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement- phase III clinical study data of xuanzhu biopharm's Anaprazole Sodium for reflux esophagitis presented at UEG Week 2026
- Voluntary announcement - polycaprolactone microsphere facial filler for Injection and hyaluronic acid sodium composite solution for Injection independently developed by meiyan space, a subsidiary of Sihuan Pharmaceutical, approved for market launch in hong kong
- Voluntary announcement-Sihuan Pharmaceutical completed a strategic investment in canton biologics to enhance the layout of the entire industrial chain of regenerative medical aesthetics
Later from Sihuan Pharmaceutical
All Sihuan Pharmaceutical news releasesFollow Sihuan Pharmaceutical into a list and get an email when it puts out news.
Follow Sihuan Pharmaceutical